DAX24.296 +0,2%ESt505.355 +0,2%Top 10 Crypto15,68 +1,2%Dow44.694 -0,7%Nas21.058 +0,2%Bitcoin100.897 +0,2%Euro1,1750 ±-0,0%Öl69,36 +1,0%Gold3.367 ±-0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Deutsche Bank 514000 Tesla A1CX3T Rheinmetall 703000 NVIDIA 918422 RENK RENK73 SAP 716460 Alphabet A (ex Google) A14Y6F Bayer BAY001 Lufthansa 823212 BASF BASF11 Deutsche Telekom 555750 Mercedes-Benz Group (ex Daimler) 710000 Infineon 623100 Siemens Energy ENER6Y Volkswagen (VW) vz. 766403
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach EZB-Zinsentscheid: US-Börsen schließen uneinig -- DAX letztendlich in Grün -- Tesla verfehlt Gewinnerwartungen -- D-Wave, Porsche, Amazon, Alphabet, BYD, Deutsche Bank, IBM im Blick
Top News
Tesla-Aktie tiefrot: Tesla verfehlt Gewinnerwartungen - Umsatz leicht über Prognose Tesla-Aktie tiefrot: Tesla verfehlt Gewinnerwartungen - Umsatz leicht über Prognose
Alphabet-Aktie in Grün: Google-Mutter meldet Gewinnsprung - Erwartungen übertroffen Alphabet-Aktie in Grün: Google-Mutter meldet Gewinnsprung - Erwartungen übertroffen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Actinium Pharmaceuticals Aktie

Handeln
Aktien-Sparplan anlegen
1,55 EUR -0,03 EUR -2,14 %
BMN
1,83 USD -0,06 USD -3,17 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.49,59 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2QA48

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00507W2061

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolATNM

Actinium Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireActinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labe...
PR NewswireATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR NewswireATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
Wer­bungActinium Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
finanzen.netActinium Pharmaceuticals stellte Ergebnisse des abgelaufenen Quartals vor
PR NewswireActinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
PR NewswireActinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer...
PR NewswireActinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Trea...
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
PR NewswireONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
PR NewswireATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR NewswireATNM Investors are Reminded of the Class Action Against Actinium Pharmaceuticals, Inc.: Contact Robbins LLP for Information About How to Become Lead Plaintiff for the Class
PR NewswireATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswireATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
finanzen.netActinium Pharmaceuticals stellte Zahlen zum jüngsten Quartal vor
PR NewswireATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswireInvestor Alert: Robbins LLP Informs Stockholders of the Actinium Pharmaceuticals, Inc. Class Action Lawsuit
PR NewswireActinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
PR NewswireActinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pip...
PR NewswireActinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today
PR NewswireActinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program
PR NewswireActinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities
PR NewswireActinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
PR NewswireActinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Mark...
PR NewswireActinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®
PR NewswireActinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
PR NewswireActinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
PR NewswireActinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with ...
PR NewswireActinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
finanzen.netActinium Pharmaceuticals: Bilanzzahlen zum vergangenen Quartal
PR NewswireActinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
PR NewswireActinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
finanzen.netActinium Pharmaceuticals stellte Quartalsergebnis zum abgelaufenen Jahresviertel vor
PR NewswireActinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
PR NewswireActinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications

Actinium Pharmaceuticals News

Actinium Pharmaceuticals News: auf dieser Seite finden Sie alle Actinium Pharmaceuticals News und Nachrichten zur Actinium Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Actinium Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Actinium Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.